Skip to main content

Chronic HBV Infection

4
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
1 program
1
GLS4Phase 21 trial
Active Trials
NCT04147208Completed250Est. Sep 2023
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
GS-4774Phase 21 trial
Active Trials
NCT01943799Completed178Est. Mar 2015
Enanta Pharmaceuticals
2 programs
2
EDP-514Phase 11 trial
EDP-514Phase 11 trial
Active Trials
NCT04470388Completed25Est. Aug 2021
NCT04008004Completed99Est. Jul 2021
Precision BioSciences
1 program
PBGENE-HBVN/A1 trial
Active Trials
NCT07254208Enrolling By Invitation45Est. Jun 2040
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
GS-4774PHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Sunshine BiopharmaGLS4
Kite PharmaGS-4774
Enanta PharmaceuticalsEDP-514
Enanta PharmaceuticalsEDP-514
Precision BioSciencesPBGENE-HBV

Clinical Trials (5)

Total enrollment: 597 patients across 5 trials

Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Start: Feb 2019Est. completion: Sep 2023250 patients
Phase 2Completed

Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

Start: Sep 2013Est. completion: Mar 2015178 patients
Phase 2Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Start: Sep 2020Est. completion: Aug 202125 patients
Phase 1Completed

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Start: Jun 2019Est. completion: Jul 202199 patients
Phase 1Completed

A Long-term Observational Study in Participants Who Have Received PBGENE-HBV

Start: Dec 2025Est. completion: Jun 204045 patients
N/AEnrolling By Invitation

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.